RankAlpha logo
Back to Rankings

JBIO

Jade BiosciencesB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
View Chart
Current thesis
The bull case is that JADE101 delivers credible Phase 1 biomarker and PK data in Q2 2026, enabling a clean transition into IgAN patient studies while JADE201 also enters the clinic on schedule. If Jade executes on both assets, investors may start valuing it as a multi-program autoimmune platform with enough capital to reach several inflection points.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +20.0.
What can break
Early biomarker success in healthy volunteers may not translate into patient efficacy in IgAN or other autoimmune indications.
Momentum
89
Value
41
Sentiment
52
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $21.00 · Bull $30.00 · Bear $14.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-21 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $45.89
Why
Momentum89 · Δ7d +20.0
Value41 · Δ7d +0.0
Sentiment52 · Δ7d -3.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
89
26% active weight
Current posture
7d trendFlat
Δ7d
+20.0
Δ21d
+51.8
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
52
34% active weight
Current posture
7d trendSoftening
Δ7d
-3.2
Δ21d
+3.4
Why this grade

Composite grade B. Momentum 89.5 / Value 41.1 / Sentiment 51.8

Fundamentals (TTM)
As of 2026-07-20
Market Cap
$1.2B
Beta
0.88
Shares Out
60.86M
P/E (TTM) · Derived
-4.8
P/S (TTM)
-
P/FCF (TTM) · Derived
-6.67
Rev YoY
-
EPS YoY
-99.9%
Gross Margin
-
Op Margin
-
Net Debt
-$335.43M
Current Ratio
14.29
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology